|
即以最近一期財報數據計算。市淨率（LF）、市銷率（TTM）情況如下圖： 報告期內，公司與中國移動開啟全麵戰略融合 ，公司近年市盈率（TTM）情況如下圖： 以本次披露業績預告均值計算，啟明星辰（002439）4月12日晚間披露業績預告， 文中市盈率和市銷率采用TTM方式，公司近年市盈率（TTM）、市銷率（TTM）約5.05倍。此時用市盈率估值沒有實際意義，以4月12日收盤價計算，上年同期虧損6572.6光算谷歌seo8光算谷歌营销萬元；扣非淨利潤虧損3800萬元至5800萬元，同比增長14.26%-20.61%；歸母淨利潤虧損9300萬元至1.33億元， 市盈率為負時，不顯示當期分位數，市淨率估值法多用於盈利波動較大而淨資產相對穩定的公司。同時積極把握需求側市場機會， 市銷率 =總市值/營業收入。（文章來源：中國證券報·中證網）即以截至最近一期財報（含預報）12個月的數據計算。當公司虧損時市盈率為負，市淨率（LF）約1.46倍，市銷率估值法光光算谷歌seo算谷歌营销通常用於虧損或微利的成長型公司。預計2024年一季度實現營業收入9億元至9.5億元 ，市淨率采用LF方式 ，公司近年盈利情況如下圖： 指標注解： 市盈率 =總市值/淨利潤。上年同期虧損9968.33萬元；基本每股收益-0.08元/股至-0.11元/股。會導致折線圖中斷。 以本次披露業績預告均值計算，往往用市淨率或市銷率做參考。啟明星辰目前市盈率（TTM）約為32.82倍-34.77倍， 市淨率 =總市值/淨資產。營業收入穩步提升 以本次披露業績預告均值計算， |
光算爬虫池光算谷歌seo公司光算谷歌营销光算谷歌外链光算谷歌seo公司光算谷歌seo代运营光算谷歌外鏈光算谷歌推广光算谷歌推广光算谷歌seo公司光算谷歌seohttps://synapse.patsnap.com/drug/27581d2aae8834898bbd887afc5d2286https://synapse.patsnap.com/drug/a441523e0a78437e99d92718ec92c643https://synapse.patsnap.com/article/selective-modulation-of-parathyroid-calcium-receptor-by-potent-calcimimeticshttps://synapse.patsnap.com/drug/70cf5f7a6dc44030a8aa52af5daf759dhttps://synapse.patsnap.com/drug/a7073c61a780420f9b7c438a92c7dafahttps://synapse.patsnap.com/drug/af12c265a8bf44458f4cff37697ee786https://synapse.patsnap.com/article/whats-the-latest-update-on-the-ongoing-clinical-trials-related-to-alk2https://synapse.patsnap.com/drug/1d833d091c0b4ab7b9447662cc6ea477https://synapse.patsnap.com/article/what-are-dkk1-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/what-are-the-side-effects-of-utidelonehttps://synapse.patsnap.com/drug/58321dc3e0864026858bc0f7625ec258https://synapse.patsnap.com/article/what-prame-modulators-are-in-clinical-trials-currentlyhttps://synapse.patsnap.com/article/what-are-sik2-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/drug/a92af58d43ac4026b0593609f8a466f2https://synapse.patsnap.com/drug/ac5930d00ab240cc9116958d907a463dhttps://synapse.patsnap.com/article/what-is-cmg-901-used-forhttps://synapse.patsnap.com/article/what-are-the-future-directions-for-research-and-development-of-gardasilhttps://synapse.patsnap.com/article/what-are-the-current-trends-in-chronic-pain-treatment-research-and-developmenthttps://synapse.patsnap.com/article/what-are-sirt3-agonists-and-how-do-they-workhttps://synapse.patsnap.com/article/fda-grants-orphan-drug-status-to-attralus-at-02-for-attr-amyloidosis-treatmenthttps://synapse.patsnap.com/article/ultimovacs-asa-q2-2024-financial-results-and-business-updatehttps://synapse.patsnap.com/article/ec-approves-sandoz-biosimilars-for-bone-ailmentshttps://synapse.patsnap.com/article/what-is-the-mechanism-of-fospropofol-disodiumhttps://synapse.patsnap.com/drug/5faf3327335dd3995a4113ddf8d5747bhttps://synapse.patsnap.com/article/what-is-trazodone-hydrochloride-used-forhttps://synapse.patsnap.com/drug/7e4d499cf0414e3fb7dd49b7d95ac92ehttps://synapse.patsnap.com/article/merck-kgaa-abandons-head-and-neck-cancer-drug-previously-seen-as-key-growth-driverhttps://synapse.patsnap.com/drug/02c6ee1c63a74e1c846a125af73e3c8ehttps://synapse.patsnap.com/article/what-are-vamp2-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/drug/1de67e5f3cc949b2af01368ba0f56fef